JNJ ▼ -0.8% - Johnson & Johnson $JNJ - Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula 19-OCT-2026 08:00 AM ET